Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Technology Sector · Saratoga Advantage

Health & Biotechnology Portfolio Health & Biotechnology Porfolio Class C (SHPCX)

Ticker SHPCX · · Holdings as of May 31, 2026

Expense ratio
3.6%$360/yr per $10k
5-yr return
+3.7%annualized
1-yr return
−1.3%as of Dec 2024
Net assets
$10.5Mall share classes
Holdings
29

Bottom line

Is SHPCX a good fund? The bottom line

SHPCX is the Health & Biotechnology Porfolio Class C share class of Health & Biotechnology Portfolio, a managed technology sector mutual fund from Saratoga Advantage.

Annual fees run 3.6% — about $360 a year on every $10,000 invested, more expensive than 100% of technology sector funds we track.

It returned −1.3% over one year, +3.7% a year over five years, +4.1% a year over ten (as of Dec 31, 2024, per its prospectus).

With $10.5 million in net assets and 29 holdings, its largest position is Cardinal Health Inc (6.4%) and the top 10 make up 50.7% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (3.6%)
  • Concentrated: top 10 holdings are 50.7% of assets
  • Small fund ($10.5 million) — small funds are likelier to close

Updated Nov 19, 2026

What SHPCX invests in

The Health & Biotechnology Portfolio seeks long-term capital growth.

The Portfolio will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or market capitalization). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends. The Adviser begins with the overall outlook for the economy, then seeks to identify specific industries with attractive characteristics and long-term growth potential. Ultimately, the Adviser seeks to identify high-quality companies within the selected industries and to acquire them at attractive prices. The Advisers stock selection process is based on an analysis of individual companies fundamental values, such as earnings growth potential and the quality of…

From the fund's prospectus (filed Dec 29, 2025).

SHPCX performance

Fund calendar-year total returns, 2015–2024 2015: +6.3%; 2016: −2.5%; 2017: +11.3%; 2018: −6.0%; 2019: +15.4%; 2020: +3.0%; 2021: +16.0%; 2022: +1.4%; 2023: −0.9%; 2024: −0.3% +6% 2015 −3% 2016 +11% 2017 −6% 2018 +15% 2019 +3% 2020 +16% 2021 +1% 2022 −1% 2023 −0% 2024
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
SHPCX−1.3%+3.7%+4.1%
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2024

Full SHPCX performance history →

What SHPCX costs

On a $10,000 investment, SHPCX's 3.6% expense ratio costs about $360 a year. The prospectus estimates $3,862 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full SHPCX fee table →

SHPCX top 10 holdings

#Holding% of fund
1Cardinal Health Inc6.44%
2Jazz Pharmaceuticals Plc6.19%
3United Therapeutics Corp6.17%
4Amgen Inc5.04%
5Mckesson Corp4.90%
6Lantheus Holdings Inc4.64%
7Exelixis Inc4.55%
8Novartis Ag4.50%
9Cencora Inc4.33%
10Gilead Sciences Inc3.94%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 50.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to SHPCX

More funds like SHPCX →

SHPCX FAQ

What is the expense ratio of SHPCX?
SHPCX's expense ratio is 3.6%, which works out to about $360 a year for every $10,000 invested. The prospectus estimates total costs of $3,862 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is SHPCX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (3.6%); concentrated: top 10 holdings are 50.7% of assets; small fund ($10.5 million) — small funds are likelier to close. This is general information, not personalized advice.
What does SHPCX hold?
SHPCX's largest holdings are Cardinal Health Inc (6.4%), Jazz Pharmaceuticals Plc (6.2%), United Therapeutics Corp (6.2%), Amgen Inc (5.0%), Mckesson Corp (4.9%). It holds 29 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is SHPCX's 5-year return?
SHPCX returned +3.7% a year over the five years ending Dec 31, 2024, and +4.1% a year over ten years. Past performance does not guarantee future results.
Does SHPCX have a sales load?
No. SHPCX has no front-end sales charge. It may charge a deferred sales charge of up to 1% if sold early.
Who manages SHPCX?
SHPCX is offered by Saratoga Advantage through Saratoga Advantage Trust.